NexoBrid

About Bharat Serums & Vaccines

BSV is a leading Indian biotech delivering patented biologics and vaccines for women's health and critical care.

About Vericel

Vericel is a revenue-generating biopharmaceutical company with a mission to provide life-enhancing cell therapies for serious medical conditions in sports medicine and burn care. The company has achieved significant commercial success with its FDA-approved products MACI (for knee cartilage defects) and Epicel (for severe burns), and has expanded its portfolio through the North American licensing of NexoBrid® for burn eschar removal. Its strategy centers on deepening market penetration for its commercial products, pursuing label expansions, and leveraging its proprietary autologous cell therapy manufacturing platform to address adjacent high-need therapeutic areas.

About Vericel

Vericel is a revenue-generating biopharmaceutical company with a mission to provide life-enhancing cell therapies for serious medical conditions in sports medicine and burn care. The company has achieved significant commercial success with its FDA-approved products MACI (for knee cartilage defects) and Epicel (for severe burns), and has expanded its portfolio through the North American licensing of NexoBrid® for burn eschar removal. Its strategy centers on deepening market penetration for its commercial products, pursuing label expansions, and leveraging its proprietary autologous cell therapy manufacturing platform to address adjacent high-need therapeutic areas.

About MediWound

MediWound is an Israeli biotech company with a mission to deliver innovative, cost-effective enzymatic solutions for severe burn care and hard-to-heal wounds. Its key achievement is the global regulatory approval and commercialization of NexoBrid, an orphan biologic for burn eschar removal, including recent FDA approval in December 2023. The company's strategy leverages a fully integrated, vertically operational model—spanning R&D, cGMP manufacturing, and targeted commercialization—to advance its core bromelain-based platform into large chronic wound markets, with EscharEx currently in Phase 3 trials.

About MediWound

MediWound is an Israeli biotech company with a mission to deliver innovative, cost-effective enzymatic solutions for severe burn care and hard-to-heal wounds. Its key achievement is the global regulatory approval and commercialization of NexoBrid, an orphan biologic for burn eschar removal, including recent FDA approval in December 2023. The company's strategy leverages a fully integrated, vertically operational model—spanning R&D, cGMP manufacturing, and targeted commercialization—to advance its core bromelain-based platform into large chronic wound markets, with EscharEx currently in Phase 3 trials.

About MediWound

MediWound is an Israeli biotech company with a mission to deliver innovative, cost-effective enzymatic solutions for severe burn care and hard-to-heal wounds. Its key achievement is the global regulatory approval and commercialization of NexoBrid, an orphan biologic for burn eschar removal, including recent FDA approval in December 2023. The company's strategy leverages a fully integrated, vertically operational model—spanning R&D, cGMP manufacturing, and targeted commercialization—to advance its core bromelain-based platform into large chronic wound markets, with EscharEx currently in Phase 3 trials.

About MediWound

MediWound is an Israeli biotech company with a mission to deliver innovative, cost-effective enzymatic solutions for severe burn care and hard-to-heal wounds. Its key achievement is the global regulatory approval and commercialization of NexoBrid, an orphan biologic for burn eschar removal, including recent FDA approval in December 2023. The company's strategy leverages a fully integrated, vertically operational model—spanning R&D, cGMP manufacturing, and targeted commercialization—to advance its core bromelain-based platform into large chronic wound markets, with EscharEx currently in Phase 3 trials.

Therapeutic Areas